Kyowa Kirin Co., Ltd. (KYKOF)
| Previous Close | 0.00 |
| Open | 22.50 |
| Bid | 20.71 x 40000 |
| Ask | 25.57 x 45900 |
| Day's Range | 22.50 - 22.50 |
| 52 Week Range | 15.78 - 22.50 |
| Volume | |
| Avg. Volume | 172 |
| Market Cap | 12.08B |
| Beta (5Y Monthly) | 0.24 |
| PE Ratio (TTM) | 16.51 |
| EPS (TTM) | 1.27 |
| Earnings Date | Oct 30, 2024 - Nov 04, 2024 |
| Forward Dividend & Yield | 0.39 (1.87%) |
| Ex-Dividend Date | Dec 27, 2024 |
| 1y Target Est | N/A |
PR NewswireNew Analysis Demonstrates Impaired Work Productivity and Increased Unemployment Rates in Adults with X-linked Hypophosphatemia (XLH)
Kyowa Kirin, Inc., an affiliate of Kyowa Kirin Co., Ltd. (Kyowa Kirin, TSE: 4151), today announced the publication of a new analysis showing low levels of full-time employment and impaired work productivity among working age adults enrolled in the XLH Disease Monitoring Program, a prospective, 10-year, observational study of adults and children with X-linked hypophosphatemia in the US, Canada, and Latin America.
- PR Newswire
Kyowa Kirin to end distribution of Fareston (toremefine) in the United States
Kyowa Kirin, Inc., an affiliate of Kyowa Kirin Co., Ltd. (Kyowa Kirin, TSE: 4151), a global specialty pharmaceutical company based in Japan, is announcing that it will no longer distribute or fulfill orders for Fareston (toremefine) 60 mg tablets in the United States, effective August 31, 2024. This decision aligns with the company's Vision for 2030 and its focus on the discovery, development and delivery of novel therapies for patients. Kyowa Kirin has previously taken steps to notify the Food
PR NewswireKyowa Kirin Announces a New Sustainable Business Strategy for the Asia-Pacific (APAC) Region
Kyowa Kirin Asia Pacific Pte. Ltd., a wholly owned subsidiary of Kyowa Kirin Co., Ltd. (Kyowa Kirin, TSE:4151, President and CEO: Masashi Miyamoto), announced plans to transform its Asia-Pacific (APAC) business for more sustainable and profitable operations, through strategic partnerships with DKSH Holding Ltd. ("DKSH") and Hong Kong Winhealth Pharma Group ("Winhealth").
